Important Safety Information Prescribing Information Patient Site

Home

THE FIRST FDA‑APPROVED, IN‑OFFICE TREATMENT FOR MOLLUSCUM

FOR AGES
2+

YCANTH®—a proven first‑line topical therapy for molluscum1

Permanent YCANTH J-code (J7354) >>

Effective April 1, 2024

image of molluscum

Efficacy data

YCANTH—demonstrated efficacy with precise administration2

DISCOVER THE DATA
image of doctor ordering product

Access and billing support

Resources to help with ordering YCANTH, billing and coding, and coverage

GET STARTED
image of doctor

YCANTH speaker program

Hear from experts on a range of topics on how YCANTH can help patients in your office

LEARN MORE

Photos are illustrative and not representative of all patients.

Applicator

Applicator is not to scale.

YCANTH—precise control with proven results2

What you should know before administering YCANTH

  • Verrica is committed to providing a training program to ensure an optimal experience
  • Counsel your patients to avoid contact with the treatment areas, including oral contact3
  • Please review Instructions for Use and see Important Safety Information throughout
  • Advise patients to read Patient Information

Y-Access® Support Solutions white glove service provides:

  • Assistance with benefit investigations and prior authorizations
  • Details about prior authorization requirements and appeals
  • Exploration of financial assistance options for Buy & Bill providers
  • Billing and coding support from Field Reimbursement Managers (FRMs), including claim submissions and resubmissions, if needed

For more information or assistance, contact Y-Access Support Solutions by calling 1-855-YCANTHS (1-855-922-6847) OR by visiting Y-AccessSupport.com.

Nurse On iPad

Model is for illustrative purposes only.

Contact us to learn more about YCANTH

LEARN MORE

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: None.

WARNINGS AND PRECAUTIONS:

  • YCANTH is for topical use only. YCANTH is not for oral, mucosal, or ophthalmic use. Life threatening or fatal toxicities can occur if YCANTH is administered orally. Avoid contact with the treatment area, including oral contact, after treatment. Ocular toxicity can occur if YCANTH comes in contact with eyes. If YCANTH gets in eyes, flush eyes with water for at least 15 minutes.

INDICATION

YCANTH (cantharidin) topical solution, 0.7% is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: None.

WARNINGS AND PRECAUTIONS:

  • YCANTH is for topical use only. YCANTH is not for oral, mucosal, or ophthalmic use. Life threatening or fatal toxicities can occur if YCANTH is administered orally. Avoid contact with the treatment area, including oral contact, after treatment. Ocular toxicity can occur if YCANTH comes in contact with eyes. If YCANTH gets in eyes, flush eyes with water for at least 15 minutes.
  • Local Skin Reactions: Reactions at the application site may occur, including vesiculation, pruritus, pain, discoloration, and erythema. Avoid application near eyes and mucosal tissue, and to healthy skin. If YCANTH contacts any unintended surface, or healthy skin, immediately remove. If severe local skin reactions occur, remove prior to the recommended 24 hours after treatment.
  • YCANTH is flammable, even after drying. Avoid fire, flame or smoking near lesion(s) during treatment and after application until removed.

ADVERSE REACTIONS:

The most common (incidence ≥1%) reactions are the following local skin reactions at the application site: vesiculation, pain, pruritus, scabbing, erythema, discoloration, application site dryness, edema, and erosion. Local skin reactions at the application site were observed in 97% of subjects treated with YCANTH during clinical trials. These local skin reactions are expected and related to the anticipated blistering response of the skin to cantharidin.

DRUG INTERACTIONS:

No studies evaluating the drug interaction potential of cantharidin have been conducted.

USE IN SPECIFIC POPULATIONS:

Pregnancy: There are no available data with use of YCANTH in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Given that systemic exposure to cantharidin following topical administration is low, maternal use is not expected to result in fetal exposure to the drug.

Lactation: Avoid application of YCANTH topical solution to areas with increased risk for potential ingestion by or ocular exposure to the breastfeeding child.

OVERDOSAGE:

Oral ingestion of cantharidin has resulted in renal failure, blistering and severe damage to the gastrointestinal tract, coagulopathy, seizures, and flaccid paralysis.

Please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Verrica Pharmaceuticals Inc. at 1-877-VERRICA (1-877-837-7422), or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Local skin reactions are expected and should be reported if they are severe.

References: 1. Centers for Disease Control and Prevention. Molluscum contagiosum: treatment options. Accessed March 12, 2024. https://www.cdc.gov/poxvirus/molluscum-contagiosum/treatment.html 2. Eichenfield LF, McFalda W, Brabec B, et al. Safety and efficacy of VP-102, a proprietary, drug-device combination product containing cantharidin, 0.7% (w/v), in children and adults with molluscum contagiosum: two phase 3 randomized clinical trials. JAMA Dermatol. 2020;156(12):1315-1323. doi:10.1001/jamadermatol.2020.3238 3. YCANTH (cantharidin) topical solution 0.7% Prescribing Information, Verrica Pharmaceuticals Inc., 2023.

FDA=Food and Drug Administration.